Compare SLDB & KRNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDB | KRNY |
|---|---|---|
| Founded | 2013 | 1884 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.6M | 494.5M |
| IPO Year | 2018 | 2005 |
| Metric | SLDB | KRNY |
|---|---|---|
| Price | $6.21 | $8.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $14.70 | $8.00 |
| AVG Volume (30 Days) | ★ 1.1M | 445.6K |
| Earning Date | 03-05-2026 | 01-22-2026 |
| Dividend Yield | N/A | ★ 5.45% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | ★ $163,144,000.00 |
| Revenue This Year | N/A | $3.89 |
| Revenue Next Year | N/A | $17.52 |
| P/E Ratio | ★ N/A | $15.65 |
| Revenue Growth | N/A | ★ 10.18 |
| 52 Week Low | $2.41 | $5.45 |
| 52 Week High | $7.37 | $8.50 |
| Indicator | SLDB | KRNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.35 | 57.32 |
| Support Level | $6.01 | $7.77 |
| Resistance Level | $7.33 | $8.28 |
| Average True Range (ATR) | 0.44 | 0.23 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 29.63 | 71.43 |
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.